GLP-1 receptor signalling promotes β-cell glucose metabolism via mTOR-dependent HIF-1α activation

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Carlessi, Rodrigo ^a,b   Chen, Younan ^a,c   Rowlands, Jordan ^a   Cruzat, Vinicius F ^a   Keane, Kevin N ^a   Egan, Lauren ^a   Mamotte, Cyril ^a   Stokes, Rebecca ^d   Gunton, Jenny E ^d,e   Bittencourt, Paulo Ivo Homem De ^b   Newsholme, Philip ^a  

^a CURTIN UNIVERSITY   (Australia)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c SICHUAN UNIVERSITY   (China)

^d UNIVERSITY OF SYDNEY   (Australia)

^e GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GLP1R PROTEIN, MOUSE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; HIF1A PROTEIN, MOUSE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; MTOR PROTEIN, MOUSE; TARGET OF RAPAMYCIN KINASE;

ANIMAL; C57BL MOUSE; CELL LINE; GLYCOLYSIS; MALE; METABOLISM; MITOCHONDRION; PANCREAS ISLET BETA CELL; RAT; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; CELL LINE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCOSE; GLYCOLYSIS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INSULIN-SECRETING CELLS; MALE; MICE, INBRED C57BL; MITOCHONDRIA; RATS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; UP-REGULATION;

EID: 85020235351     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-02838-2     Document Type: Article

References (50)

1. Henquin, J. C. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 49, 1751-1760, doi:10.2337/diabetes.49.11.1751 (2000).
2. Ashcroft, F. M. et al. Stimulus-Secretion Coupling in Pancreatic Beta-Cells. J Cell Biochem 55, 54-65, doi:10.1002/jcb.240550007 (1994).
3. Granhall, C., Rosengren, A. H., Renstrom, E. &Luthman, H. Separately inherited defects in insulin exocytosis and beta-cell glucose metabolism contribute to type 2 diabetes. Diabetes 55, 3494-3500, doi:10.2337/db06-0796 (2006).
4. Drucker, D. J. &Nauck, M. A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368, 1696-1705, doi:10.1016/S0140-6736(06)69705-5 (2006).
5. DeFronzo, R. A. et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes care 28, 1092-1100 (2005).
6. Vilsboll, T. et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes care 30, 1608-1610, doi:10.2337/dc06-2593 (2007).
7. Baggio, L. L. &Drucker, D. J. Biology of incretins: GLP-1 and GIP. Gastroenterology 132, 2131-2157, doi:10.1053/j.gastro.2007.03.054 (2007).
8. Seino, S. &Shibasaki, T. PKA-dependent and PKA-independent pathways for cAMP-regulated exocytosis. Physiological reviews 85, 1303-1342, doi:10.1152/physrev.00001.2005 (2005).
9. Light, P. E., Fox, J. E. M., Riedel, M. J. &Wheeler, M. B. Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein kinase A- and ADP-dependent mechanism. Molecular endocrinology 16, 2135-2144, doi:10.1210/me.2002- 0084 (2002).
10. Kang, G. X., Leech, C. A., Chepurny, O. G., Coetzee, W. A. &Holz, G. G. Role of the cAMP sensor Epac as a determinant of K-ATP channel ATP sensitivity in human pancreatic beta-cells and rat INS-1 cells. J Physiol-London 586, 1307-1319, doi:10.1113/ jphysiol.2007.143818 (2008).
11. MacDonald, P. E. &Wheeler, M. B. Voltage-dependent K+ channels in pancreatic beta cells: Role, regulation and potential as therapeutic targets. Diabetologia 46, 1046-1062, doi:10.1007/s00125-003-1159-8 (2003).
12. Kang, G. X. et al. A cAMP and Ca2+ coincidence detector in support of Ca2+ induced Ca2+ release in mouse pancreatic beta cells. J Physiol-London 566, 173-188, doi:10.1113/jphysiol.2005.087510 (2005).
13. Wu, B. et al. Synaptotagmin-7 phosphorylation mediates GLP-1-dependent potentiation of insulin secretion from beta-cells. Proceedings of the National Academy of Sciences of the United States of America, doi:10.1073/pnas.1513004112 (2015).
14. Meloni, A. R., DeYoung, M. B., Lowe, C. &Parkes, D. G. GLP-1 receptor activated insulin secretion from pancreatic ss-cells: mechanism and glucose dependence. Diabetes Obesity &Metabolism 15, 15-27, doi:10.1111/j.1463-1326.2012.01663.x (2013).
15. Peyot, M. L. et al. Glucagon-like peptide-1 induced signaling and insulin secretion do not drive fuel and energy metabolism in primary rodent pancreatic beta-cells. PloS one 4, e6221, doi:10.1371/journal.pone.0006221 (2009).
16. Van de Velde, S., Hogan, M. F. &Montminy, M. mTOR links incretin signaling to HIF induction in pancreatic beta cells. Proceedings of the National Academy of Sciences of the United States of America 108, 16876-16882, doi:10.1073/pnas.1114228108 (2011).
17. Semenza, G. L. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. Journal of applied physiology 88, 1474-1480 (2000).
18. Semenza, G. L. HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 20, 51-56, doi:10.1016/j. gde.2009.10.009 (2010).
19. Faubert, B. et al. Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1 alpha. Proceedings of the National Academy of Sciences of the United States of America 111, 2554-2559, doi:10.1073/pnas.1312570111 (2014).
20. Semenza, G. L., Roth, P. H., Fang, H. M. &Wang, G. L. Transcriptional Regulation of Genes Encoding Glycolytic-Enzymes by Hypoxia-Inducible Factor-1. Journal of Biological Chemistry 269, 23757-23763 (1994).
21. Xu, G., Stoffers, D. A., Habener, J. F. &Bonner-Weir, S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48, 2270-2276, doi:10.2337/diabetes.48.12.2270 (1999).
22. Tourrel, C., Bailbe, D., Meile, M. J., Kergoat, M. &Portha, B. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 50, 1562-1570, doi:10.2337/diabetes.50.7.1562 (2001).
23. Berg, J. M., Tymoczko, J. L. &Stryer, L. Biochemistry. 5th edn, (Freeman, W.H. 2002).
24. Ferrick, D. A., Neilson, A. &Beeson, C. Advances in measuring cellular bioenergetics using extracellular flux. Drug Discov Today 13, 268-274, doi:10.1016/j.drudis.2007.12.008 (2008).
25. Nie, J. et al. SAD-A kinase controls islet beta-cell size and function as a mediator of mTORC1 signaling. Proceedings of the National Academy of Sciences of the United States of America 110, 13857-13862, doi:10.1073/pnas.1307698110 (2013).
26. Buteau, J., Foisy, S., Joly, E. &Prentki, M. Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes 52, 124-132 (2003).
27. Yuan, H. X., Xiong, Y. &Guan, K. L. Nutrient sensing, metabolism, and cell growth control. Mol Cell 49, 379-387, doi:10.1016/j. molcel.2013.01.019 (2013).
28. Semenza, G. L. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. The Journal of clinical investigation 123, 3664-3671, doi:10.1172/JCI67230 (2013).
29. Xie, J. et al. Exendin-4 stimulates islet cell replication via the IGF1 receptor activation of mTORC1/S6K1. Journal of molecular endocrinology 53, 105-115, doi:10.1530/JME-13-0200 (2014).
30. Miao, X. Y. et al. The human glucagon-like peptide-1 analogue liraglutide regulates pancreatic beta-cell proliferation and apoptosis via an AMPK/mTOR/P70S6K signaling pathway. Peptides 39, 71-79, doi:10.1016/j.peptides.2012.10.006 (2013).
31. Holz, G. Gt, Kuhtreiber, W. M. &Habener, J. F. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature 361, 362-365, doi:10.1038/361362a0 (1993).
32. Kjems, L. L., Holst, J. J., Volund, A. &Madsbad, S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on betacell sensitivity in type 2 and nondiabetic subjects. Diabetes 52, 380-386 (2003).
33. Bunck, M. C. et al. Effects of Exenatide on Measures of beta-Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes. Diabetes care 34, 2041-2047, doi:10.2337/dc11-0291 (2011).
34. Retnakaran, R., Kramer, C. K., Choi, H., Swaminathan, B. &Zinman, B. Liraglutide and the preservation of pancreatic beta-cell function in early type 2 diabetes: the LIBRA trial. Diabetes care 37, 3270-3278, doi:10.2337/dc14-0893 (2014).
35. Gudipaty, L. et al. Effect of exenatide, sitagliptin, or glimepiride on beta-cell secretory capacity in early type 2 diabetes. Diabetes care 37, 2451-2458, doi:10.2337/dc14-0398 (2014).
36. McClenaghan, N. H. et al. Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion. Diabetes 45, 1132-1140 (1996).
37. Green, B. D. et al. Lys(9) for Glu(9) substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39). Metabolism-Clinical and Experimental 53, 252-259, doi:10.1016/j.metabol.2003.09.015 (2004).
38. Hodson, D. J. et al. Incretin-modulated beta cell energetics in intact islets of Langerhans. Molecular endocrinology 28, 860-871, doi:10.1210/me.2014-1038 (2014).
39. Tsuboi, T. et al. Glucagon-like peptide-1 mobilizes intracellular Ca2+ and stimulates mitochondrial ATP synthesis in pancreatic MIN6 beta-cells. Biochemical Journal 369, 287-299, doi:10.1042/Bj20021288 (2003).
40. Gheni, G. et al. Glutamate acts as a key signal linking glucose metabolism to incretin/cAMP action to amplify insulin secretion. Cell Rep 9, 661-673, doi:10.1016/j.celrep.2014.09.030 (2014).
41. Park, J. H. et al. Glucagon-Like Peptide-1 Enhances Glucokinase Activity in Pancreatic beta-Cells through the Association of Epac2 with Rim2 and Rab3A. Endocrinology 153, 574-582, doi:10.1210/En.2011-0259 (2012).
42. Ding, S. Y., Nkobena, A., Kraft, C. A., Markwardt, M. L. &Rizzo, M. A. Glucagon-like peptide 1 stimulates post-translational activation of glucokinase in pancreatic beta cells. The Journal of biological chemistry 286, 16768-16774, doi:10.1074/jbc. M110.192799 (2011).
43. Schmidt, S. F. et al. Integrative Genomics Outlines a Biphasic Glucose Response and a ChREBP-RORgamma Axis Regulating Proliferation in beta Cells. Cell Rep 16, 2359-2372, doi:10.1016/j.celrep.2016.07.063 (2016).
44. National Research Council (U.S.). Committee for the Update of the Guide for the Care and Use of Laboratory Animals, Institute for Laboratory Animal Research (U.S.) &National Academies Press (U.S.). xxv, 220 p. (National Academies Press, Washington, D.C. 2011).
45. Dixon, G., Nolan, J., McClenaghan, N., Flatt, P. R. &Newsholme, P. A comparative study of amino acid consumption by rat islet cells and the clonal beta-cell line BRIN-BD11 - the functional significance of L-alanine. Journal of Endocrinology 179, 447-454, doi:10.1677/joe.0.1790447 (2003).
46. Szot, G. L., Koudria, P. &Bluestone, J. A. Murine pancreatic islet isolation. Journal of visualized experiments: JoVE 255, doi:10.3791/255 (2007).
47. Zou, C. H., Wang, Y. J. &Shen, Z. F. 2-NBDG as a fluorescent indicator for direct glucose uptake measurement. J Biochem Bioph Meth 64, 207-215, doi:10.1016/j.jbbm.2005.08.001 (2005).
48. Keane, K. N., Calton, E. K., Cruzat, V. F., Soares, M. J. &Newsholme, P. The Impact of Cryopreservation on Human Peripheral Blood Leukocyte Bioenergetics. Clinical science. doi:10.1042/CS20140725 (2015).
49. Salceda, S. &Caro, J. Hypoxia-inducible factor 1 alpha (HIF-1 alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions - Its stabilization by hypoxia depends on redox-induced changes. Journal of Biological Chemistry 272, 22642-22647, doi:10.1074/jbc.272.36.22642 (1997).
50. Schepens, B., Tinton, S. A., Bruynooghe, Y., Beyaert, R. &Cornelis, S. The polypyrimidine tract-binding protein stimulates HIF-1 alpha IRES-mediated translation during hypoxia. Nucleic acids research 33, 6884-6894, doi:10.1093/nar/gki1000 (2005)